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2.  SURGERY IN PATIENTS WITH METASTATIC 
DISEASE
Radical nephrectomy has been indicated even for r c c  
patients with metastatic disease. Two phase iii studies 
randomized patients to i f nα with or without cytore-
ductive radical nephrectomy. In a combined analysis 
of these trials, median survival was 7.8 months in 
patients treated with i f nα alone as compared with 13.6 
months for patients who received i f nα plus cytoreduc-
tive nephrectomy 9–11. A greater survival advantage 
was observed in patients with better performance 
status. This cytoreductive paradigm remains predomi-
nant in the era of targeted therapy  because clinical 
trials demonstrating the benefits of targeted therapy 
have largely been observed in the context of prior 
nephrectomy 12–16. It remains to be seen whether the 
observation of shrinkage in the primary tumour with 
targeted agents may alter this paradigm in future. A 
randomized trial to clarify the value of cytoreductive 
nephrectomy is currently in development (A. Ravaud, 
personal communication).
Although cytoreductive nephrectomy appears to 
benefit many patients with metastatic r c c , it is not 
curative, and it should not be performed indiscrimi-
nately. Patients who are most likely to benefit from 
cytoreduction include those with
•   substantial tumour burden (for example, in excess 
of 75%) in the involved kidney,
• good performance status, and
•   no central nervous system or liver metastases 
(with rare exceptions) 17.
Other considerations pertain to surgical resect-
ability, particularly the potential for morbidity if 
proximity to vital structures, encasement of the 
renal hilum, or other complicating factors are 
present. Because of lower operative morbidity and 
mortality, laparoscopic nephrectomy is emerg-
ing as the standard surgical procedure whenever 
technically feasible.
ABSTRACT
Targeted therapy has greatly changed the way in 
which metastatic renal cell carcinoma (r c c) is treated. 
Agents that inhibit the vascular endothelial growth 
factor and mammalian target of rapamycin pathways 
that otherwise lead to angiogenesis have now become 
the standard of care. Much research into the sequence 
and combination of these agents is ongoing, and new 
anti-angiogenic agents are being developed. This 
overview covers the standard treatment of metastatic 
r c c  with targeted therapy, immunotherapy, and sur-
gery. Future directions and ongoing clinical trials are 
also discussed.
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1.  INTRODUCTION
Metastatic renal cell carcinoma (r c c) is estimated 
to have caused 13,010 deaths in the United States in 
2008 1. Previously, immunotherapy agents such as 
interleukin-2 and interferon alpha (i f nα) were the 
only treatments available, and they demonstrated 
low response rates of approximately 15% 2–7. The 
biology underlying r c c  has been elucidated, and 
agents targeting relevant biologic pathways have 
been investigated 8. This targeting developed chiefly 
from an understanding of von Hippel–Lindau 
(v h l) syndrome, which is an inherited, autosomal 
dominant genetic disorder that commonly manifests 
in the development of clear-cell r c c  in affected 
patients. The present review details the current 
evidence behind traditional approaches, including 
cytoreductive nephrectomy, metastasectomy, and 
immunotherapy, and then provides an overview 
of the contemporary targeted therapies and related 
ongoing clinical trials.STATE-OF-THE-ART TREATMENT OF METASTATIC RCC
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Patients with disseminated r c c  and a solitary 
metastasis may be considered for metastasectomy, 
although they represent a small fraction of cases. 
Favourable prognostic factors include a long interval 
between initial diagnosis and development of the 
metastasis, which reflects an indolent course and 
reinforces the likelihood that the metastasis is truly 
solitary. Additionally, complete resection of the 
metastatic disease should be possible (for example, 
solitary pulmonary nodule), so that the patient can 
be said to have no evidence of disease 18. Patients 
with favourable-to-intermediate prognostic features 
may achieve a 5-year survival of 38%–71% with 
metastasectomy, and thus surgical resection of 
metastases should be considered in appropriately 
selected r c c  patients 19.
3.  IMMUNOTHERAPY
Early trials using chemotherapy did not produce a 
significant benefit 20,21, and so, in an attempt to har-
ness the innate immune response of r c c tumours, 
immunotherapy has long been the standard of care 
for the treatment of metastatic r c c . Treatment with 
i f nα produced response rates of up to 15%, with 
modest to no prolongation of overall survival (o s ), 
in comparisons with inactive controls 5,6. A pooled 
analysis investigating the use of high-dose interleu-
kin-2 (il-2) revealed an overall response rate (o r r ) of 
14%, with 5% complete responses 22. Most patients 
achieving a complete response had durable disease 
remission. Notably, significant side effects were 
observed, including capillary leak syndrome, which 
necessitated intensive blood pressure monitoring and 
the occasional requirement for vasopressors.
Phase iii trials of high-dose il-2 failed to demon-
strate significant benefit in comparisons with low-dose 
cytokine regimens 2,3. High-dose il-2 is noteworthy 
for a small but real percentage of durable complete 
remissions; however, this treatment strategy is able to 
be applied only in a small, highly selected fraction of 
r c c cases. Even the occasional patient with very ex-
tensive disease, including involvement of lung, bone, 
or liver, may sustain a remission measured in years. 
Attempts to precisely characterize and identify this 
group of responders have been uniformly unsuccess-
ful, however, which makes the use of this treatment 
strategy very challenging.
4.  BIOLOGIC BASIS OF TARGETED THERAPY: 
vHL
The recognition of hereditary renal neoplasms cata-
lyzed the discovery of the genetic basis of r c c. Clini-
cally, the v h l  syndrome, a constellation of cysts and 
tumours in the central nervous system and abdominal 
viscera 8, is inherited in an autosomal dominant 
fashion. The central nervous system lesions include 
retinal hemangioblastomas, endolymphatic sac tumours, 
and craniospinal hemangioblastomas. The visceral 
lesions in these patients include clear-cell r c c s, 
pheochromocytomas, neuroendocrine pancreatic 
tumours, epididymal cystadenomas, and broad liga-
ment cystadenomas.
Patients with v h l  syndrome have an aberrant 
vHl allele on chromosome 3p25, which predisposes 
them to disease if the second allele is mutated. This 
configuration is a prime example of the classical “two-
hit hypothesis” for genes with a tumour-suppressor 
function. The v h l  213-amino-acid protein polyubiqui-
nates hypoxia-inducible factor (h i f ), which marks 
that factor for destruction by the cellular proteasome. 
Normally, low oxygen conditions allow h i f α to ac-
cumulate and bind to h i f β, thereby creating a complex 
that transcriptionally activates genes. In patients with 
aberrant vHl, h i f α is left to freely accumulate without 
degradation, even under normal oxygen conditions. 
Thus, the transcription of genes related to glucose 
metabolism, apoptosis, angiogenesis, and endothelial 
stabilization are abnormally promoted. This disordered 
response to hypoxia activates more than 100 h i f -
responsive genes that include growth factors and their 
receptors such as vascular endothelial growth factor 
(v e g f ), platelet-derived growth factor (p d g f ), and 
transforming growth factors alpha and beta 23.
Nonhereditary, sporadic clear-cell r c c also exhib-
its vHl aberrations 23. A single vHl allele deletion 
occurs in approximately 78.4%–98% of sporadic 
tumours 24–29. For the remaining allele, vHl gene 
mutations are seen in 34%–57%, and gene inactivation 
via hypermethylation of CpG–rich d n a  islands oc-
curs in about 5%–20.4% of clear-cell r c c 24,27,28,30,31. 
Thus, it is clear that, in hereditary and sporadic cases 
of clear-cell r c c alike, vHl abnormalities are a key 
in the pathogenesis.
5.  TARGETED THERAPY
With an understanding of the biology behind meta-
static r c c , new drugs have been developed to target 
downstream effectors of v h l  and h i f  (Table i), includ-
ing v e g f , p d g f , and mammalian target of rapamycin 
(mt o r ). Drugs such as sunitinib and sorafenib target 
the v e g f  receptor (v e g f r ), and drugs such as beva-
cizumab target the v e g f  ligand. Other drugs such as 
temsirolimus and everolimus target downstream ef-
fectors of v e g f , including mt o r  kinase. All of these 
drugs have demonstrated efficacy in the treatment of 
metastatic r c c  and have been incorporated into the 
current treatment algorithm (Table ii).
5.1  VEGFR Tyrosine Kinase Inhibitors
Receptor tyrosine kinases (r t k s) play an integral role 
in the signalling cascade of v e g f  and p d g f  34. An ex-
tracellular domain of the r t k s binds to the respective 
ligand, and an intracellular domain holds the tyrosine 
kinase responsible for downstream signalling. Upon HENG and KOLLMANNSBERGER
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ligand binding, the r t k s dimerize or multimerize to 
induce a conformational change that permits binding 
of adenosine triphosphate, resulting in autophospho-
rylation and transphosphorylation. These tyrosine 
domains are then able to phosphorylate and activate 
various proteins in the downstream signal transduc-
tion cascade.
5.1.1  Sunitinib
Sunitinib is an oral multikinase inhibitor that blocks 
v e g f r s 1, 2, and 3, p d g f  receptor beta and related r t k s 35. 
Initial phase ii trials of sunitinib in metastatic r c c (in 
169 patients who had failed prior cytokine-based ther-
apy) demonstrated an investigator-assessed objective 
response rate of 45%, a median duration of response 
of 11.9 months, and a median progression-free survival 
(p f s) of 8.4 months 36–38.
The pivotal phase iii randomized controlled trial 
(750 patients) compared first-line sunitinib with i f nα 
and demonstrated a statistically significant advantage 
in objective response rate (39% vs. 8%, p < 0.000001) 
and p f s (11 months vs. 5 months) with a hazard ratio 
(h r) of 0.42 (p < 0.001) 12. The median o s  of the 
sunitinib and interferon groups was 26.4 months and 
21.8 months respectively, which was of borderline 
statistical significance (p = 0.051), likely because 
patients who progressed on i f nα were allowed to 
cross over to receive v e g f -targeted therapy 32. Notably, 
most of the enrolled patients (94%) had a favourable 
or intermediate risk by Memorial Sloan–Kettering 
Cancer Center (m s k c c ) prognostic criteria 39. Com-
mon toxicities included fatigue, hand–foot syndrome, 
diarrhea, mucositis, hypertension, and hypothyroid-
ism. Cardiotoxicity has been reported, and thus 
t a b l e  i Selected clinical trials of targeted agents in metastatic renal cell carcinoma
  Agent  Mechanism    Efficacy
          Population    Trial    r r   p f S   O S
              arms    (%)    (months)    (months)
Sunitinib 12,32  Tyrosine kinase  First line  Sunitinib  39  11  26.4
    inhibitor of v e g f    vs. interferon  8  5  21.8
      and related receptors            p<0.000001    p<0.001   p =0.051
Sorafenib 13  Tyrosine kinase  Treatment-  Sorafenib  10  5.5  17.8
    inhibitor of v e g f   refractory,  vs. placebo  2  2.8  15.2
      and related receptors    second line    p<0.001    p<0.01  p=0.146
Temsirolimus 16  Inhibitor of mt o r   Poor-risk  Temsirolimus  8.6  n a   10.9
      first line  vs. interferon  4.8  n a   7.3
              n s       p<0.008
Bevacizumab 14,33  v e g f  ligand–binding  First line  Bevacizumab  31, 25  10.2, 8.5  n a
    antibody    plus interferon
        vs. placebo  13, 13  5.4, 5.2  n a
              plus interferon    p<0.0001    p<0.0001
r r  = risk ratio; p f s = progression-free survival; o s  = overall survival; v e g f  = vascular endothelial growth factor; mt o r  = mammalian target 
of rapamycin; n a  = not available; n s  = nonsignificant.
t a b l e  ii Current treatment algorithm for patients with metastatic renal cell carcinoma
  Setting  Patients  Therapy  Alternatives
      (level1evidence)
First-line    Good or intermediate risk  Sunitinib  High-dose interleukin-2
      Bevacizumaba plus interferon  Sorafenib
        Observation
        Clinical trial
    Poor risk  Temsirolimus  Sunitinib
        Clinical trial
Second-line  Cytokine-refractory  Sorafenib  Sunitinib
        Bevacizumaba plus interferon
        Clinical trial
    Prior v e g f  or mt o r   Everolimusa  Targeted therapy
      Clinical trial  not previously used
        Clinical trial
a Everolimus and bevacizumab are not yet approved by the U.S. Food and Drug Administration for metastatic renal cell carcinoma.
v e g f  = vascular endothelial growth factor; mt o r  = mammalian target of rapamycin.STATE-OF-THE-ART TREATMENT OF METASTATIC RCC
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monitoring may be required in patients with pre-
existing heart disease 40.
Because of these phase ii and iii trials, sunitinib 
has become a standard of care for the first-line treat-
ment of metastatic r c c .
5.1.2  Sorafenib
Sorafenib was initially investigated for its ability to 
inhibit the Raf protein kinase, thereby affecting the 
mitogen-activated protein kinase signalling pathway 
responsible for downstream proliferation responses. 
However, it subsequently became clear that activity 
against v e g f r  2, v e g f r  3, p d g f  beta, Flt-3, and c-Kit 
was also present 41.
The Treatment Approaches in Renal Cancer 
Global Evaluation Trial, the largest study of previ-
ously-treated metastatic clear-cell r c c , enrolled 903 
patients who were randomized either to oral sorafenib 
400 mg twice daily or placebo 13. All patients enrolled 
had favourable or intermediate risk m s k c c  prognostic 
criteria. A clear median p f s benefit (5.5 months vs. 2.8 
months) was observed in the sorafenib group. Objec-
tive response rate was minimal (10%, investigator-
assessed), although more than 70% of patients had 
some degree of tumour burden reduction. The toxici-
ties commonly experienced with sorafenib are similar 
to those experienced with sunitinib, except that the 
hand–foot syndrome may be more pronounced, and 
cardiotoxicity appears to occur less frequently.
Based on these data, sorafenib has been approved 
by the U.S. Food and Drug Administration (f d a ) and 
has become a standard of care for second-line treat-
ment of metastatic r c c  after immunotherapy failure. 
However, in a randomized phase ii trial of first-line 
sorafenib versus i f nα, a p f s benefit could not be dem-
onstrated 42. Thus, sorafenib has assumed a largely 
second-line or later role in the treatment of metastatic 
r c c . The exception is the first-line use of sorafenib in 
patients unsuitable for sunitinib.
5.2  VEGF Ligand–Directed Therapy
Bevacizumab is a recombinant monoclonal antibody 
that binds and neutralizes circulating v e g f. The ac-
tivity of this agent in r c c  was initially identified by 
small randomized trials 43,44. A subsequent phase iii 
clinical trial randomized nephrectomized patients 
with clear-cell metastatic r c c  to the combination of 
i f nα (three times weekly at a dose of 9×106 IU for up 
to 1 year) plus bevacizumab [10 mg/kg intravenously 
(IV) every 2 weeks], or i f nα with placebo until dis-
ease progression 14. The addition of bevacizumab 
to i f nα significantly increased p f s (10.2 months vs. 
5.4 months; h r: 0.63; p < 0.0001) and the objective 
tumour response rate (31% vs. 13%, p < 0.0001). A 
trend toward improved o s  was observed with the 
addition of bevacizumab, although results are not 
yet mature (p = 0.0670). A Cancer and Leukemia 
Group B phase iii trial of similar design confirmed 
a p f s (8.5 months vs. 5.2 months, p < 0.0001) and 
an o r r  (25% vs. 13%, p < 0.0001) benefit with be-
vacizumab plus i f nα 33. The final analysis of o s  is 
pending. Common toxicities included hypertension 
and proteinuria, with rare but serious toxicity includ-
ing bowel perforation, arterial ischemic events, and 
bleeding.
Whether bevacizumab must be given in combi-
nation with interferon is unknown, because no beva-
cizumab monotherapy arm was used in the phase iii 
trials. Nevertheless, bevacizumab is important in the 
armamentarium of treatments for r c c  and f d a  approval 
is pending.
5.3  mTOR Inhibitors
Another downstream effect of the v e g f r  pathway 
is activation of Akt and phosphoinositide 3 kinase, 
which in turn promote mt o r  kinase. A component 
of intracellular pathways, mt o r  promotes tumour 
growth and proliferation, and is a mediator of the 
hypoxic response.
5.3.1  Temsirolimus
Temsirolimus is an f d a -approved mt o r  inhibitor 
that binds to FK506 binding protein 1A to create a 
complex that directly inhibits mt o r . A phase iii trial 
included 626 previously untreated patients with poor 
prognostic criteria and randomized them to temsiroli-
mus 25 mg IV weekly, i f nα 18×106 IU 3 times weekly, 
or temsirolimus plus i f nα 3 times weekly 16. Patients 
were required to have 3 or more of the following 
adverse risk features:
Karnofsky performance status below 80 • 
Lactate dehydrogenase more than 1.5 times the  • 
upper limit of normal
Hemoglobin below the lower limit of normal • 
Serum corrected calcium above 10 mg/dL • 
Less than 1 year from first diagnosis of  •  r c c  to 
start of therapy
Three or more metastatic sites • 
Of the patients included in this trial, 19% had 
non-clear-cell or unknown histology. Temsirolimus 
monotherapy demonstrated an o s  advantage in com-
parison with i n f α (10.9 months vs. 7.3 months, log-
rank p < 0.008). The o r r  was 8.6% for temsirolimus 
and 4.8% for interferon, which was not a statistically 
significant difference. Common side effects included 
fatigue, hypercholesterolemia, and hyperglycemia. 
Temsirolimus has become a first-line standard of care 
for patients with metastatic r c c, appropriately applied 
to patients with poor prognostic criteria.
5.3.2  Everolimus
Another mt o r  inhibitor, everolimus (RAD001), has 
recently been reported in a phase iii trial to improve 
the p f s of patients with metastatic r c c  who progressed HENG and KOLLMANNSBERGER
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on sunitinib, sorafenib, or both 45. These patients were 
randomized to daily oral everolimus 10 mg or placebo 
and were stratified by number of previous tyrosine 
kinase inhibitors (t k i s) and m s k c c  “previously treated” 
risk groups (1 point each for anemia, hypercalcemia, 
and Karnofsky performance status below 80, with 
0 points = favourable risk, 1 point = intermediate risk, 
and 2+ points = poor risk). The primary endpoint was 
p f s, and in the RAD001 and placebo groups, that 
endpoint was 4.0 months and 1.9 months respectively 
(p < 0.0001). For the two groups, the o s  was not 
reached and 8.8 months respectively (p = 0.233, but 
the analysis is not yet mature). The benefit in p f s was 
seen in all three m s k c c  risk groups. Common side 
effects included asthenia, anemia, and stomatitis. This 
is the first second-line trial after initial t k i  failure to 
demonstrate benefit. Regulatory approval is pending.
6.  DRUGS IN DEvELOPMENT
Axitinib (AG013736) is a small-molecule t k i  of v e g f r , 
p d g f  receptor, and c-Kit. A phase ii trial enrolled 
62 treatment-refractory patients with r c c that had 
progressed on sorafenib 46. They were treated with 
oral axitinib 5 mg twice daily. Of 62 patients, 13 
exhibited a partial response, and the median p f s was 
7.4 months. An earlier phase ii trial enrolled cytokine-
refractory nephrectomized patients who demonstrated 
a response rate of 44.2% and a median time to pro-
gression of 15.7 months with axitinib 47. Currently, 
a large multicentre phase iii trial is enrolling patients 
that progressed on sunitinib and is randomizing them 
to axitinib or sorafenib (search for “NCT00678392” 
at clinicaltrials.gov/ct2/search).
Pazopanib (GW786034) is another t k i  of v e g f r s 
1–3, p d g f  receptors alpha and beta, and c-Kit. A ran-
domized discontinuation study was initiated in patients 
who were treatment naïve (68%) or who had one line 
of immunotherapy (25%), bevacizumab (3%), or 
other non-targeted therapy (2%). The first 60 patients 
demonstrated good disease control rates, leading the 
Data and Safety Monitoring Committee to stop the 
discontinuation randomization phase and to allow all 
patients to continue the drug. Among the 225 patients 
with metastatic r c c enrolled, an o r r  of 27% was ob-
served by independent review at 12 weeks 48. A first-
line pazopanib versus sunitinib randomized controlled 
trial is currently recruiting (search for “NCT00720941” 
at clinicaltrials.gov/ct2/search).
Cediranib (AZD2171) is an potent inhibitor of 
v e g f r s 1–3, p d g f  receptor beta, and Flt-4. This oral 
agent has been studied by the Princess Margaret 
Hospital Consortium in a phase ii trial as first-line 
treatment in patients with progressive, unresectable, 
advanced metastatic r c c  49. Preliminary results indi-
cate a partial response rate of 38% (6/16 patients). 
An additional 6 patients had stable disease, and 3 
patients had progressive disease. Further trials exam-
ining this agent are warranted.
Volociximab is a chimeric monoclonal antibody 
against α5β1 integrin. The antibody blocks fibronec-
tin in the extracellular matrix from binding to α5β1 
integrin, inducing apoptosis of proliferating endothe-
lial cells. Volociximab was studied in a multicentre 
phase ii study in patients with metastatic clear-cell 
r c c  that enrolled 40 evaluable patients. It was well 
tolerated at 10 mg/kg given IV every 2 weeks. One 
subject achieved a partial response, and 32 subjects 
had stable disease 50.
Inhibitors of c-Met such as XL880 and ARQ197 
have been developed with the knowledge that genetic 
alterations in papillary r c c  are different from those in 
clear-cell r c c . In patients with heritable disease, the 
c-met proto-oncogene on chromosome 7 is frequently 
duplicated 51. XL880 and ARQ197 are inhibitors of 
the c-Met r t k , which is mutated in most heritable pap-
illary cancers and in some sporadic papillary cancers. 
Dose-finding phase i studies have been completed 52,53, 
and these novel agents are currently being studied 
in patients with metastatic papillary r c c  in phase ii 
trials (search for “NCT00345423” at clinical trials.
gov/ct2/search). Preliminary results for XL880 (an 
inhibitor of c-Met and v e g f r  2) have been reported in 
a phase ii trial that enrolled 20 evaluable patients: 3 
of those patients had partial responses, and none had 
progressive disease 54. Of the patients enrolled in the 
phase i ARQ197 trial, 5 had advanced r c c . Of those 
5 patients, 3 had stable disease, 1 had progressive 
disease, and 1 has yet to be reported 53.
7.  FUTURE DIRECTIONS
Targeted therapies have now replaced the relatively 
ineffective complement of immunotherapeutic agents 
used in patients with metastatic r c c. Whether targeted 
therapies are best given in sequence or in combination, 
and what their role in the perioperative setting might 
be, is currently unclear.
A phase ii trial has completed enrolment of pa-
tients who progressed on sunitinib or bevacizumab 
and who are now receiving sorafenib based on the 
rationale that sorafenib may have non-cross-resistant 
activity in these patients. Of the 37 patients enrolled, 
52% have experienced tumour shrinkage (defined as 
a 5% or greater decrease in tumour measurements), 
and 14% have experienced a true partial response by 
the Response Evaluation Criteria in Solid Tumors 55. 
These findings demonstrate that patients that have 
progressed on one v e g f  inhibitor can still respond 
to another v e g f  inhibitor. However, the effects of 
these second-line strategies on p f s or o s  are currently 
unclear and can be determined only in randomized 
trials, which are ongoing. At the present time, it re-
mains unknown whether a patient who progressed on 
a v e g f  inhibitor should then be exposed to another t k i  
or should be treated using an agent with a different 
mechanism of action (for example, the mt o r  inhibitor 
temsirolimus). A phase iii randomized trial in patients STATE-OF-THE-ART TREATMENT OF METASTATIC RCC
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refractory to sunitinib is currently comparing temsi-
rolimus with sorafenib (search for “NCT00474786” 
at clinicaltrials.gov/ct2/search).
Studies combining targeted therapies are being 
performed with the known caveat that combination 
therapies are associated with high financial cost and 
possibly increased toxicity because of overlapping 
side-effect profiles. A phase i trial of bevacizumab 
and sunitinib in a variety of solid tumours (led by 
the Cleveland Clinic) reported 1 unconfirmed partial 
response in a patient with papillary r c c  from among 
9 evaluable patients 56. Another phase i trial of this 
combination, given exclusively to patients with 
metastatic r c c , reported partial responses in 4 of 
13 patients 57. A randomized phase ii trial studying 
the combination of bevacizumab and erlotinib [an 
inhibitor of the epidermal growth factor receptor 
(e g f r ) pathway] as compared with bevacizumab and 
placebo revealed no benefit for the active combina-
tion in terms of o r r  or p f s  44. Currently, combina-
tions of targeted therapy remain experimental, and 
they should be administered only in the context of 
a clinical trial.
Targeted agents are also being studied in the 
adjuvant setting for patients with resected high-risk 
r c c  and in the neoadjuvant setting in an attempt to 
downstage tumours before surgical resection of lo-
calized disease. The Adjuvant Sorafenib or Sunitinib 
for Unfavorable Renal Carcinoma Intergroup trial 
randomizes high-risk nephrectomized patients to 
one year of sorafenib, sunitinib, or placebo. Other 
trials such as the Sunitinib Trial in Advanced Renal 
Cancer (search for “NCT00326898” at clinicaltrials.
gov/ct2/search) and the sorafenib versus placebo trial 
in patients with resected intermediate- or high-risk 
r c c  (search for “NCT00492258” at clinicaltrials.gov/
ct2/search) will help to elucidate the effect of these 
agents in the adjuvant setting. In the neoadjuvant 
setting, sunitinib in two preoperative cycles is being 
studied in a phase ii trial (search for “NCT00480935” 
at clinicaltrials.gov/ct2/search).
8.  CONCLUSIONS
Targeted therapy has changed the landscape of treat-
ment options for metastatic r c c . The disordered re-
sponse to hypoxia found in r c c  has been harnessed, 
making v e g f, p d g f, and mt o r-directed pathways a 
standard of care. This change has led to improved 
response rates and prolonged survival. New drug 
development, sequencing and combinations of 
drugs, and use of targeted drugs in the adjuvant 
and neoadjuvant settings are the subjects of ongoing 
clinical trials.
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